NEONATAL RESPIRATORY TRIALS IN SICK & PRETERM NEWBORN INFANTS
Professor Brett J. Manley, Consultant Neonatologist
Mercy Hospital For Women, Melbourne & Professor of Neonatal Medicine, Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | August 2025
Professor Brett J. Manley is a Consultant Neonatologist at the Mercy Hospital for Women in Melbourne, Australia, and a Professor of Neonatology in the Department of Obstetrics, Gynaecology and Newborn Health at The University of Melbourne. His research is supported by a fellowship from the National Health and Medical Research Council (NHMRC), Australia.
He divides his work time between being a clinician in the neonatal intensive care unit (NICU), and a clinical researcher. He is passionate about caring for sick and preterm newborn infants and contributing to the evidence base for their care, to improve their shorter- and longer-term outcomes.
Prof Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
Source: Supplied
You Might also like
-
Genetic alterations in prostate cancer initiation and progression
Watch Dr Kelsie Raspin, a dedicated Postdoctoral Research Fellow specialising in Cancer Genetics at Menzies Institute for Medical Research, University of Tasmania, talk on bridging a critical knowledge gap in the understanding of genetic alterations implicated in prostate cancer initiation and its progression into metastatic forms.
-
Good and bad extracellular vesicles in health and disease
Associate Professor Joy Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, and through her work at the AIBN, she aims to develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer.
-
Dr Meghan McIlwain
DR MEGHAN MCILWAIN, CLINICAL RESEARCH MANAGER
PRESIDENT, THE NEW ZEALAND ASSOCIATION OF CLINICAL RESEARCH,
AUCKLAND, NEW ZEALAND